
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a healthcare service provider focused on developing drugs for metabolic and endocrine disorders, with a diverse clinical program pipeline consisting of VK2809, VK5211, and VK0214 products. The company's lead asset, VK2735, is a dual GLP-1/GIP peptide agonist with two formulations: daily oral (Phase 2 ongoing) and weekly subcutaneous (Phase 3-ready). Viking is also developing DACRA compounds for obesity, and management's discussion of competitive dynamics and potential partnerships in employer-based models and ex-U.S. markets increases strategic optionality and supports adoption. Additionally, strong cash runway through key value-driving milestones, including Phase 3 development and potential benefits beyond weight loss for VK2735, positions Viking for long-term success.
Bears say
Viking Therapeutics is an established drug development company that faces potential risks and uncertainties in its clinical trials and the competitive commercial market. While it has shown promise in its clinical program pipeline, there is no guarantee that the company's products will be successful or that it will be able to secure adequate funding. Additionally, our valuation and assumptions for the commercial potential of Viking's products contribute to our negative outlook on the stock.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares